A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 77
- 试验地点
- 27
- 主要终点
- Incidence of Related Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them, leading to fewer red blood cells than in normal.
TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events.
The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways:
- TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort).
- TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort).
Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will have a follow-up visit at the clinic 4 weeks later.
详细描述
This is a follow-up study to the Phase 3 pivotal study (281102 [NCT03393975]) and will be comprised of two treatment cohorts (Prophylactic and On-demand) consisting of naïve and non-naïve participants who were born with TTP, with a total duration of approximately 6 years. A maximum of approximately 77 participants will be enrolled in this study (approximately 57 participants who have completed study 281102 [NCT03393975] [non-naïve participants] and at least 20 naïve participants (participants who are naïve to TAK-755). Participants from Expanded Access Programs, participants from study 281102 (NCT03393975) who had an allergic reaction to standard of care treatment, and participants who completed the Phase 1 study (281101 [NCT02216084]) but did not participate in Study 281102, will also be eligible for enrollment in this continuation study as naïve participants.
TAK-755 is given slowly through a vein (intravenous infusion). Participants in the prophylactic cohort will be able to opt for treatment in a home setting by caregiver or self-infusion subject to conditions and to local regulatory approval.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who have completed TAK-755 Phase 3 pivotal Study 281102 (NCT03393975) in the prophylactic cohort and who meet all of the following criteria are eligible for this study:
- •Participants or legally authorized representative has provided signed informed consent >=18 years of age and/or assent form <18 years of age.
- •Participant 0 to 70 years of age at the time of screening of the 281102 (NCT03393975) study.
- •Participant has been diagnosed with severe congenital ADAMTS-13 deficiency.
- •Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count <100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (>) 2 × ULN at screening (prophylactic cohort only).
- •Participants >=16 years of age must have a Karnofsky score >= 70% and participants <16 years of age must have a Lansky score >=80%.
- •If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
- •Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered.
- •Participant is willing and able to comply with the requirements of the protocol.
- •All naïve participants and non-naïve on-demand cohort participants:
- •Naïve participants can only be enrolled in this continuation after enrollment of the adult participants in the prophylactic arm of TAK-755 Phase 3 pivotal study 281102 (NCT03393975) has been completed. Naïve pediatric participants can be enrolled after enrollment of the respective age cohort into the pivotal Phase 3 study 281102 (NCT03393975) has been completed. The following criteria also applies to participants who completed study 281101 (NCT02216084), but did not participate in 281102 (NCT03393975).
- •Naïve participants and participants who were enrolled into the on-demand cohort of theTAK-755 Phase 3 pivotal study 281102 (NCT03393975) who meet ALL of the following criteria are eligible for this study:
- •Participant is naïve or was enrolled into the on-demand cohort of the TAK-755 Phase 3 pivotal study 281102 (NCT03393975) for treatment of an acute TTP event but did not receive prophylactic treatment.
- •Participant or legally authorized representative has provided signed informed consent (>=18 years of age) and/or assent form (<18 years of age).
- •Participant is 0 to 70 years of age at the time of screening.
- •Participant has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:
- •Confirmed by molecular genetic testing, documented in participant history or at screening, and
- •ADAMTS-13 activity <10% as measured by the fluorescence resonance energy transfer (FRETS)-VWF73 assay, documented in participant history or at screening. Participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS-13 activity at screening.
- •Participants currently receiving prophylactic therapy will be screened immediately prior to their usual prophylactic infusion.
- •Participant does not display any severe TTP signs (platelet count <100,000/microliter (mcL) and elevation of LDH >2 × ULN) at screening (prophylactic cohort only).
- •Participants >=16 years of age must have a Karnofsky score >=70% and participants <16 years of age must have a Lansky score >=80%.
- •Participants is hepatitis C virus negative (HCV-) as confirmed by antibody or polymerase chain reaction testing OR HCV positive (HCV+) if their disease is chronic but stable.
- •If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
- •Sexually active males must use an accepted and effective method of contraception during treatment and until a minimum of 16 days after the last dose administered.
- •Participant is willing and able to comply with the requirements of the protocol.
- •Participants from an Expanded Access Program or participants in Study 281102 (NCT03393975) who had an allergic reaction to standard of care prophylactic treatment must meet all of the following criteria:
- •Participants from an expanded access program as well as participants who participated in Study 281102(NCT03393975) who had an allergic reaction to standard-of-care prophylactic treatment are eligible for enrollment in the continuation study if they meet ALL of the following criteria.
- •Participants or legally authorized representative has provided signed informed consent (>=18 years of age) and/or assent (<18 years of age).
- •Participants is 0 to 70 years of age at the time of screening.
- •Participants has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:
- •Confirmed by molecular genetic testing, documented in participant history or at screening, and
- •ADAMTS-13 activity <10% as measured by the fluorescence resonance energy transfer (FRETS)- VWF 73 assay, documented in participant history or at screening. Participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS 13 activity at screening.
- •Participant does not display any severe TTP signs (platelet count <100,000/mcL and elevation of LDH >2 × ULN) at screening (prophylactic cohort only).
- •Participants >=16 years of age must have a Karnofsky score >=70% and participants <16 years of age must have a Lansky score >=80%.
- •If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ highly effective birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
- •Sexually active males must use an accepted and effective method of contraception during treatment and until a minimum of 16 days after the last dose administered.
- •Participant is willing and able to comply with the requirements of the protocol.
排除标准
- •Participants who have completed TAK-755 Phase 3 pivotal study (281102) (NCT03393975) and naïve participants and non-naïve on-demand cohort participants and participants from an Expanded Access Program or participants in Study 281102 (NCT03393975) who had an allergic reaction to standard-of-care prophylactic treatment. The following criteria also applies to participants who completed study 281101 (NCT02216084), but did not participate in 281102 (NCT03393975).
- •Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including immune-mediated TTP.
- •Known life-threatening hypersensitivity reaction, including anaphylaxis, to the parent molecule ADAMTS-13, hamster protein, or other constituents of TAK-
- •Participant has a presence of a functional ADAMTS-13 inhibitor at screening.
- •Participant has a medical history of a genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are human immunodeficiency virus-positive with an absolute cluster of differentiation 4 (CD4) count < 200/ cubic millimeter (mm^3) or who are receiving chronic immunosuppressive drugs.
- •Participant has a history of significant neurological events, such as major stroke, indicating that a relapse might have severe consequences, as judged by the investigator.
- •Participant has been diagnosed with severe cardiovascular disease (New York Heart Association classes 3 to 4).
- •Participant with end stage renal disease requiring chronic dialysis.
- •Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following:
- •Serum alanine aminotransferase >= 2 × ULN
- •Severe hypoalbuminemia <24 gram per liter (g/L)
- •Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal varices).
- •In the opinion of the investigator, the participant has another clinically significant concomitant disease that may pose additional risks for the participant.
- •Participant has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of corticosteroids in conjunction with administration of fresh frozen plasma to prevent allergic reactions is permitted.
- •Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylactic cohort only).
- •Participant is receiving or anticipates receiving another investigational drug and/or interventional drug within 30 days before enrollment.
- •Participant has a history of drug and/or alcohol abuse within the last 2 years.
- •Participant has a progressive fatal disease and/or life expectancy of <= 3 months.
- •Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.
- •Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude.
- •Participant is a family member or employee of the sponsor or investigator.
- •If female, participant is pregnant or lactating at the time of enrollment.
- •In the UK only: Participants who have not previously received a dose of TAK-755.
研究组 & 干预措施
Prophylactic Cohort: TAK-755
All participants will receive prophylactic treatment with 40 IU/kg TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study.
Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with 40 IU/kg TAK-755 by IV infusion once every week or once every other week for the duration of the study.
干预措施: TAK-755 (Biological)
On-Demand Cohort: TAK-755
Participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved.
Participants will receive 40 IU/kg TAK-755 on the first day, followed by 20 IU/kg on Day 2, and then 15 IU/kg daily until 2 days after the acute TTP event has resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study.
干预措施: TAK-755 (Biological)
结局指标
主要结局
Incidence of Related Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
时间窗: Throughout the study period of approximately 6 years
TEAE: any adverse event emerging or manifesting at or after the initiation of treatment with TAK-755 or any existing adverse event that worsens in either intensity or frequency following exposure to TAK-755. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event.
次要结局
- Number of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events in Participants with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Undergoing Prophylactic Treatment with TAK-755(Up to approximately 3 years)
- Incidence Rate of Acute TTP Events in Participants with cTTP Undergoing Prophylactic Treatment with TAK-755(Up to approximately 3 years)
- Incidence of Acute TTP Events while Participants are on Their Final Dose and Dosing Regimen(Throughout the study period of approximately 6 years)
- Incidence of Thrombocytopenia(Up to approximately 3 years)
- Number of Acute TTP Events Resolved After Treatment with TAK-755 while Enrolled in the Study(Throughout the study period of approximately 6 years)
- Proportion of Acute TTP Events Resolved After Treatment with TAK-755 while Enrolled in the Study(Throughout the study period of approximately 6 years)
- Time to Resolution of Acute TTP Events Following Treatment with IP(Throughout the study period of approximately 6 years)
- Total Quantity of TAK-755 Administered During the Treatment of Acute TTP Events(Throughout the study period of approximately 6 years)
- Incidence of Neurological Symptoms(Up to approximately 3 years)
- Incidence of Renal Dysfunction(Up to approximately 3 years)
- Incidence of TTP Manifestations While Receiving the Final Prophylactic Treatment Regimen with TAK-755 in the Home Setting(Up to approximately 3 years)
- Incidence of Supplemental Doses Prompted by Subacute TTP Events(Up to approximately 3 years)
- Incidence of Dose Modifications Not Prompted by an Acute TTP Event(Up to approximately 3 years)
- Incidence of Acute TTP Events in Participants Receiving TAK-755 Prophylactically in the Home Setting(Up to approximately 3 years)
- Incidence of all AEs and SAEs (Including Unrelated)(Throughout the study period of approximately 6 years)
- Proportion of Participants with anti-ADAMTS13 Binding Antibodies and Neutralizing Antibodies Following ADAMTS13 Administration(Throughout the study period of approximately 6 years)
- HRQoL: Abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)(Throughout the study period of approximately 6 years)
- HRQoL: EuroQol 5 Dimensions Questionnaire 3-Level (EQ-5D-3L)(Throughout the study period of approximately 6 years)
- HRQoL: Pediatric Quality of Life Inventory (Peds QL)(Throughout the study period of approximately 6 years)
- incidence of Abdominal Pain(Up to approximately 3 years)
- Incidence of Microangiopathic Hemolytic Anemia(Up to approximately 3 years)
- Incidence of TTP Manifestations for Participants Receiving TAK-755 as a Prophylactic Treatment(Up to approximately 3 years)
- Number of Participants Experiencing TAK-755 Related AEs and SAEs After Receiving TAK-755 in the Home Setting(Throughout the study period of approximately 6 years)
- Resource Utilization: Length of Hospital Stay for Acute TTP Events(Throughout the study period of approximately 6 years)
- Resource Utilization: Number of Participants with Days Missed From School or Work due to TTP-Related Illness(Throughout the study period of approximately 6 years)
- Assessment of Von Willebrand Factor: Ristocetin Cofactor Activity (VWF:RCo)(At trough pre-infusion and 65 minutes post-infusion at interval study visits every 12 weeks (up to 6 years))
- Number of Participants with AEs and SAEs After Receiving TAK-755 in the Home Setting(Throughout the study period of approximately 6 years)
- Health Related Quality of Life (HRQoL): cTTP-Specific Patient reported outcomes (PROs)(Throughout the study period of approximately 6 years)
- HRQoL: 36-Item Short Form Health Survey (SF-36)(Throughout the study period of approximately 6 years)
- HRQoL: EQ-5D-youth (EQ-5D-Y)(Throughout the study period of approximately 6 years)
- HRQoL: Infusion Experience Satisfaction Assessment Questionnaire(Throughout the study period of approximately 6 years)
- Resource Utilization: Number of Hospitalizations for Acute TTP Events(Throughout the study period of approximately 6 years)
- Resource Utilization: Number of Participants with Healthcare Resource Utilization During Prophylaxis(Up to approximately 3 years)
- Assessment of Trough and Postdose ADAMTS13 Activity: Antigen Levels (Activity:Ag)(At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years))
- Assessment of Von Willebrand Factor: Antigen (VWF:Ag)(At trough pre-infusion and 65 minutes post-infusion at interval study visits every 12 weeks (up to 6 years))
- Assessment of VWF:Ag in Relation to ADAMTS13 Activity Levels(At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years))
- Assessment of VWF:RCo in Relation to ADAMTS13 Activity Levels(At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years))
- Number of Participants with Acute and Subacute Events in Relation with ADAMTS13 Activity Levels(At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years))